Diös Signs 15-year Green Lease With Evidensia For Gävle Property

Diös Fastigheter signed a 15-year green lease with Evidensia Sverige for approximately 1,000 sqm at the Södertull 13:8 property in Gävle, converting vacant office space into veterinary premises; the lease was signed in December 2025 with occupancy scheduled for September 2026 and redevelopment to begin spring 2026. The SEK 24 million redevelopment is expected to deliver a yield-on-cost of just over 9% and includes joint measures to reduce energy use and climate impact under the green lease; Evidensia operates more than 80 clinics in Sweden. Diös shares closed down 1.90% at SEK 64.55 on the Stockholm exchange.

Analysis

Market structure: This deal is accretive at the project level — SEK 24m capex for ~1,000 sqm with >9% yield-on-cost and a 15‑year lease materially improves Diös’s near-term cash returns and lowers vacancy risk in Gävle. Direct winners: Diös Fastigheter (DIOS.ST) and healthcare/clinic operators with long-term, specialised tenants; losers: landlords with large central-office exposure and no conversion pipeline (higher re-leasing risk and capex). The transaction signals sustained demand for non-traditional office conversions in secondary Swedish cities and a willingness to accept sub-10% cap rates for long leases with ESG clauses.

Risk assessment: Tail risks include capex overruns, Evidensia renegotiating or defaulting (low-probability but high-impact for a concentrated 1,000 sqm lease), and broader cap‑rate expansion if Swedish rates rise >100bp (which would knock NAV and offset the 9% yield). Immediate market effect is negligible; material P&L impact is short-to-medium term (spring–Sep 2026 redevelopment → occupancy Sept 2026) and full valuation recognition occurs over 1–3 years as NOI stabilises. Hidden dependency: project economics assume stable energy-costs and permit timelines — delays compress IRR quickly.

Trade implications: Tactical long DIOS exposure is justified ahead of redevelopment start (spring 2026) and rent commencement (Sept 2026); quantify as 2–3% portfolio with 10% stop and 20% 12‑month target upside. Pair trades: long DIOS vs short office‑centric peers (e.g., FABG.ST) to isolate execution/tenant mix alpha. Options: use calendar/vertical spreads to express directional view into 2026 catalysts while capping premium (e.g., Jan 2027 65/80 call spread). Rebalance away from pure-office REITs into specialised healthcare/long‑lease assets.

Contrarian angles: Market may underweight the optionality from repeatable conversion playbooks — if Diös can scale similar 5–10 projects/year, EPS accretion is multi-year. Conversely, the market could be underestimating concentration risk from a few long tenants and municipal planning/energy-cost inflation. Historical parallel: post‑COVID office-to-healthcare/education conversions delivered outsized returns when execution costs stayed within 10–15% of budget; if costs exceed 25%, returns flip negative. A disciplined capex runway and warranty/contract protections are the key idiosyncratic risk mitigant.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Diös Fastigheter (DIOS.ST) within 30 trading days, target price SEK 78 (~+20% from SEK 64.55) within 12 months, stop-loss at SEK 58 (≈‑10%); increase to 4–5% if Diös announces two additional conversion lease deals within 6 months.
• Implement a pair trade: long DIOS.ST (equal notional) and short Fabege (FABG.ST) sized 1:1 to express preference for landlords executing niche conversions; hold 6–12 months and rebalance if relative performance diverges >8%.
• Buy a capped upside option: enter Jan 2027 DIOS 65/80 call spread (pay max premium representing ≤1.5% portfolio risk) to capture redevelopment and occupancy catalysts (spring–Sept 2026) while limiting downside premium loss.
• Reduce exposure to pure-office Swedish REITs by 25% over the next 90 days (target names: FABG.ST and other central‑Stockholm office‑heavy REITs) and redeploy proceeds into healthcare-anchored property names or DIOS-type conversion plays.